H.C. Wainwright lowered the firm’s price target on Moleculin Biotech (MBRX) to $8 from $45 and keeps a Buy rating on the shares. The firm adjusted its model to the effect of a 1-for-15 reverse ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback